ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Ganciclovir"

  • 2022 American Transplant Congress

    Cytomegalovirus Prevention in Kidney and Pancreas Transplant Recipients: A Successful Pharmacist-Led Multidisciplinary Approach

    J. Geyston, J. Dann, A. Doyle, A. Agarwal, K. Brayman, C. Shoemaker, C. Lester, S. Rao

    University of Virginia Health, Charlottesville, VA

    *Purpose: In response to high cytomegalovirus (CMV) infection and increasing ganciclovir (GCV)-resistance rate, a pharmacist-led multidisciplinary task force was created to manage CMV prophylaxis (ppx).…
  • 2022 American Transplant Congress

    Post-Kidney Transplant Valacyclovir or Valganciclovir for EBV Prophylaxis: A Randomized Controlled Trial

    P. S. Verghese1, A. Matas2, S. Chinnakotla2, M. Evans3, H. Balfour Jr4

    1Pediatric Nephrology, Northwestern University, Feinberg School of Medicine, Minneapolis, MN, 2Surgery, University of Minnesota Medical School, Minneapolis, MN, 3Biostatistics, University of Minnesota, Minneapolis, MN, 4Lab Medicine & Pathology, University of Minnesota, Minneapolis, MN

    *Purpose: EBV viremia post-kidney transplant (KTx) has no proven prophylaxis.*Methods: In this randomized, open-label trial [NCT01329185], adult and pediatric recipients were randomly assigned (1:1) to…
  • 2022 American Transplant Congress

    Preemptive Therapy in Cytomegalovirus (CMV) Seropositive Donor to Seronegative Recipient Liver Transplants

    J. Revollo, E. Aldag, K. Cooper, B. Noell, V. Casingal, K. Gajurel

    Transplant, Atrium Health's Carolinas Medical Center, Charlotte, NC

    *Purpose: To evaluate if a preemptive therapy strategy can prevent CMV disease and induce CMV seroconversion.*Methods: Observational data collection for CMV D+/R- adult liver transplant…
  • 2021 American Transplant Congress

    Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience

    S. Alharbi1, A. Aljedai2, D. Alkortas2

    1Pharmaceutical Care Division, KFSH&RC, riyadh, Saudi Arabia, 2Pharmaceutical Care Division, KFSH&RC, Riyadh, Saudi Arabia

    *Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…
  • 2021 American Transplant Congress

    Ganciclovir Therapeutic Drug Monitoring in Obese Adults Patients – Opportunity for Clinical Utility

    Y. Tran1, S. Bernard1, R. W. Stevens1, L. Myhre1, R. Razonable2

    1Department of Pharmacy, Mayo Clinic, Rochester, MN, 2Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN

    *Purpose: Ganciclovir (GCV) is the drug of choice for the treatment of cytomegalovirus (CMV) infection; optimal dosing of GCV in the obese patient population is…
  • 2021 American Transplant Congress

    An Unusual Viral Tropism in a Solid Organ Transplant Recipient

    P. Singh, A. Bentall, C. Langstraat, A. Swanson, P. Deziel, Y. Huang, R. Razonable

    Mayo Clinic, Rochester, MN

    *Purpose: Cytomegalovirus (CMV) tissue-invasive disease occurs in higher proportion in CMV-mismatched kidney transplant recipients (KTxR) with no pre-existing immunity and those who are markedly immunologically-impaired.…
  • 2020 American Transplant Congress

    Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients

    L. Al Bizri1, Z. S. Chaudhry2, A. Vahia2, J. Williams2, J. C. Lemos-Ramirez3, B. Summers4, A. Patel5, S. Nagai6, O. Abreu Lanfranco2, M. Ramesh2, R. Del Busto2, G. Alangaden2

    1Internal Medicine, Henry Ford Health System, Detroit, MI, 2Infectious Disease, Henry Ford Health System, Detroit, MI, 3Department of Transplant Infectious Disease, Memorial Regional Hospital, Hollywood, FL, 4Central Pharmacy, Henry Ford Health System, Detroit, MI, 5Nephrology, Henry Ford Health System, Detroit, MI, 6Surgery Transplant, Henry Ford Health System, Detroit, MI

    *Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…
  • 2020 American Transplant Congress

    Valganciclovir Prophylaxis is Not Associated with Polyomavirus Viremia after Renal Transplantation

    D. Conti1, D. Schuster1, M. Garner1, E. Maciera1, S. Patel2

    1Albany Medical Center, Albany, NY, 2Surgery, Albany Medical Center, Albany, NY

    *Purpose: Recent studies have implicated prophylactic valganciclovir (VGC) therapy after renal transplantation to be associated with an increased rate of BK polyomavirus viremia and nephropathy.…
  • 2019 American Transplant Congress

    Ganciclovir Based Prophylaxis against Cytomegalovirus Viremia in Pediatric Renal Transplant Patients: A Systematic Review and Meta-Analysis

    B. CHATANI1, W. Glaberson2, Z. Nemeth3, L. Tamariz4, I. A. Gonzalez1

    1Pediatric Infectious Disease, University of Miami Miller School of Medicine, Miami, FL, 2Pediatric Nephrology, University of Miami Miller School of Medicine, Miami, FL, 3Health Informatics, University of Miami Miller School of Medicine, Miami, FL, 4Population Health and Computation Medicine, University of Miami Miller School of Medicine, Miami, FL

    *Purpose: Cytomegalovirus (CMV) disease continues to stand as a significant threat to the longevity of renal transplants in children. More pediatric recipients are CMV negative…
  • 2019 American Transplant Congress

    Lower Rates of Epstein-Barr Virus Viremia and Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients Who Received Valganciclovir Prophylaxis

    E. A. Moulton1, M. Karandikar2, S. Bond3, S. Burchett2, T. Sharma2, F. M. Marty3

    1Baylor College of Medicine, Houston, TX, 2Boston Children's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA

    *Purpose: Antiviral prophylaxis to prevent post-transplant lymphoproliferative disease (PTLD) remains controversial, but some data suggest that valganciclovir or ganciclovir use in Epstein-Barr virus (EBV) high-risk…
  • 1
  • 2
  • 3
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences